氯氮平治疗前ACKR1/Duffy-null基因检测指南
该指南由英国CERSI-PGx制定,针对氯氮平治疗中因ADAN(ACKR1/DARC相关中性粒细胞减少)导致的不必要停药问题,提出在现有临床路径中开展ACKR1基因检测的框架,并推荐对Duffy-null基因型者采用调整后的白细胞/中性粒细胞阈值进行监测。
要点
- 推荐对所有开始氯氮平治疗者进行先发性ACKR1基因检测。
- 对中央不再挑战数据库注册者及血结果低于阈值(琥珀色或红色)者进行检测。
- Duffy-null基因型者应使用修订后的ADAN白细胞/中性粒细胞阈值监测。
核心结论
- ACKR1基因检测是促进氯氮平可及性的成本效益策略,氯氮平是难治性精神分裂症的最佳治疗。
研究设计与样本
- 该指南由英国监管科学与创新药物基因组学卓越中心(CERSI-PGx)制定,基于现有临床路径提出检测框架。
关键数值与推荐
- 推荐三条资格标准:所有开始氯氮平者先发性检测、中央不再挑战数据库注册者检测、血结果低于阈值(琥珀色或红色)后反应性检测。
- Duffy-null基因型者应使用修订后的ADAN白细胞/中性粒细胞阈值监测。
- 无论ACKR1基因型,白细胞<2.0×10^9/L和/或中性粒细胞<1.0×10^9/L且出现关键临床特征(如持续体温≥38°C)者需血液学输入。
临床怎么用
- 在氯氮平治疗路径中整合ACKR1基因检测,对Duffy-null基因型者采用调整后的血细胞监测阈值,避免不必要的停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clozapine is licenced for treatment-resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis. Some people have naturally low ANCs without increased infection risk, caused by a homozygous T > C variant in ACKR1, commonly called the Duffy-null genotype. This condition is known as ADAN (ACKR1/DARC-associated neutropenia) and synonyms include DANC (Duffy-null associated neutrophil count) and BEN (benign ethnic neutropenia). It is usual UK practice to lower WBC/ANC thresholds for people confirmed to have ADAN. However, ADAN often remains undetected, resulting in unnecessary discontinuation and exclusion from clozapine. This CERSI-PGx guideline provides a framework to offer ACKR1 genotype testing within the existing clinical pathway. We recommend three eligibility criteria, including pre-emptive testing for all people starting clozapine, testing for people registered in the Central Non-Rechallenge Database and reactive testing following a below-threshold blood result (defined as 'amber' or 'red'). We recommend that people with the Duffy-null genotype should be monitored using revised WBC/ANC thresholds for ADAN. Regardless of ACKR1 genotype, haematology input is required for people returning a WBC < 2.0 × 109/L and/or ANC < 1.0 × 109/L who present with a key clinical feature, such as sustained temperature ≥38°C. Finally, we summarize health economic evidence, estimating in the first year of testing, 129 people with the Duffy-null genotype could be identified, resulting in savings ranging from £42 732 to £727 990. We propose ACKR1 testing as a cost-effective approach for facilitating access to clozapine, the optimal therapy for treatment-resistant schizophrenia.
引用
- Murtough S, Stellakis O, Mills D, et al. ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2026. PMID: 42125771. doi:10.1002/bcp.70576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。